Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

Crypto@FirstSquawk on XFiled 3 days ago

A post by @FirstSquawk on X.

Open the post on XPosted by @FirstSquawk on x.com

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

The U.S. FDA approved Gazyva for adults with primary membranous nephropathy. The decision marks a new regulatory milestone for the Roche drug in a kidney disease indication. It matters because it expands Gazyva's label beyond its existing uses and gives patients a newly sanctioned treatment option. Watch for Roche's pricing and launch details, plus any update to peak sales estimates.

Muhabbit's AI wrote this summary of @FirstSquawk's post in its own words. It can get details wrong, so read the post on X.

Named in this story

Gazyva, US FDA, Primary Membranous Nephropathy